Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
candesartan + cilnidipine
- Development stage
- Phase 4
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Candesartan + cilnidipine is a fixed-dose combination (FDC) medication primarily indicated for the treatment of essential hypertension. It combines candesartan cilexetil, a long-acting angiotensin II receptor blocker (ARB), with cilnidipine, a unique calcium channel blocker (CCB). Candesartan acts by selectively antagonizing the AT1 receptor, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. Cilnidipine distinguishes itself from conventional CCBs by providing dual blockade of both L-type calcium channels (located in vascular smooth muscle) and N-type calcium channels (located in sympathetic nerve endings). This dual mechanism allows for effective vasodilation while simultaneously suppressing sympathetic overactivity, which helps prevent reflex tachycardia and provides superior renoprotective effects compared to L-type-only CCBs. The combination is widely utilized in Asian markets, particularly Japan and India, for patients whose blood pressure is not adequately controlled by monotherapy.
- Brand names
- Atelec-CCilacar-CNexovas-CCilaheart-CCilny-CCilamet-C
- Other names
- candesartan cilexetil + cilnidipine
02
Targets
LTCC (Voltage-gated calcium channel (L-type))CACNA1B (Voltage-dependent N-type calcium channel subunit alpha-1B)AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on candesartan + cilnidipine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on candesartan + cilnidipine.